Diagnostics Partnering Terms and Agreements is a new market research publication announced by Reportstack. This report provides comprehensive understanding and unprecedented access to the diagnostic partnering agreements entered into by the worlds leading healthcare companies.
This report provides details of the latest diagnostics agreements announced in the healthcare sectors, covering:
Companion Diagnostics
Imaging
CT
Endoscope
Molecular and nuclear
MRI
Ultrasound
X-ray
PET
SPECT
Angiography
Fluroscopy
Mammography
In vitro diagnostics
Molecular diagnostics
Prognostics
Theranostics
The report provides a detailed understanding and analysis of how and why companies enter diagnostic partnering deals. The majority of deals are development stage whereby the licensee obtains a right or an option right to license the licensors diagnostic technology or product candidates. These deals tend to be multicomponent, starting with collaborative R&D, and commercialization of outcomes.
Understanding the flexibility of a prospective partner’s negotiated deals terms provides critical insight into the negotiation process in terms of what you can expect to achieve during the negotiation of terms. Whilst many smaller companies will be seeking details of the payments clauses, the devil is in the detail in terms of how payments are triggered – contract documents provide this insight where press releases and databases do not.
The initial chapters of this report provide an orientation of diagnostics dealmaking and business activities. Chapter 1 provides an introduction to the report, whilst chapter 2 provides an overview of the trends in diagnostics dealmaking since 2009, including details of average headline, upfront, milestone and royalty terms and big pharma and big biotech activities.
Chapter 3 provides a review of the leading diagnostics deals since 2009. Deals are listed by headline value and signed by big pharm. Where the deal has an agreement contract published at the SEC a link provides online access to the contract.
Chapter 4 provides a comprehensive listing of the top 50 big pharma companies that have announced diagnsotic deals, with a brief summary followed by a comprehensive listing of diagnostics deals, as well as contract documents available in the public domain. Where available, each deal title links via Weblink to an online version of the actual contract document, providing easy access to each contract document on demand.
Chapter 5 provides a comprehensive listing of the top 50 big biotech companies that have announced diagnsotic deals, where diagnostic deals are announced with a brief summary, as well as contract documents available in the public domain. Where available, each deal title links via Weblink to an online version of the actual contract document, providing easy access to each contract document on demand.
Chapter 6 provides a comprehensive and detailed review of diagnostics partnering deals signed and announced since January 2009, where a contract document is available in the public domain. The chapter is organized by cpmpany A-Z, stage of development at signing, deal type (collaborative R&D, co-promotion, licensing etc), and specific therapy focus. Each deal title links via Weblink to an online version of the deal record and where available, the contract document, providing easy access to each contract document on demand.
Chapter 7 provides a comprehensive and detailed review of diagnostics partnering deals signed and announced since January 2009. The chapter is organized by specific diagnostics technology type in focus. Each deal title links via Weblink to an online version of the deal record and where available, the contract document, providing easy access to each contract document on demand.
The report also includes numerous tables and figures that illustrate the trends and activities in diagnostics partnering and dealmaking since 2009.
In conclusion, this report provides everything a prospective dealmaker needs to know about partnering in the research, development and commercialization of diagnostics technologies and products.
Report scope
Diagnostics Partnering Terms and Agreements is intended to provide the reader with an in-depth understanding of the diagnostic trends and structure of deals entered into by leading companies worldwide.
Diagnostics Partnering Terms and Agreements includes:
Trends in diagnostic dealmaking in the biopharma industry since 2009
Analysis of diagnostic deal structure
Case studies of real-life diagnostic deals
Access to over 3,000 diagnostic deals
The leading diagnostic deals by value since 2009
Most active diagnostic dealmakers since 2009
The leading diagnostic partnering resources
In Diagnostics Partnering Terms and Agreements , the available contracts are listed by:
Headline value
Stage of development at signing
Deal component type
Specific therapy target
Each deal title links via Weblink to online deal records of actual diagnostics partnering deals as disclosed by the deal parties. In addition, where available, records include contract documents as submitted to the Securities Exchange Commission by companies and their partners."
This report provides details of the latest diagnostics agreements announced in the healthcare sectors, covering:
Companion Diagnostics
Imaging
CT
Endoscope
Molecular and nuclear
MRI
Ultrasound
X-ray
PET
SPECT
Angiography
Fluroscopy
Mammography
In vitro diagnostics
Molecular diagnostics
Prognostics
Theranostics
The report provides a detailed understanding and analysis of how and why companies enter diagnostic partnering deals. The majority of deals are development stage whereby the licensee obtains a right or an option right to license the licensors diagnostic technology or product candidates. These deals tend to be multicomponent, starting with collaborative R&D, and commercialization of outcomes.
Understanding the flexibility of a prospective partner’s negotiated deals terms provides critical insight into the negotiation process in terms of what you can expect to achieve during the negotiation of terms. Whilst many smaller companies will be seeking details of the payments clauses, the devil is in the detail in terms of how payments are triggered – contract documents provide this insight where press releases and databases do not.
The initial chapters of this report provide an orientation of diagnostics dealmaking and business activities. Chapter 1 provides an introduction to the report, whilst chapter 2 provides an overview of the trends in diagnostics dealmaking since 2009, including details of average headline, upfront, milestone and royalty terms and big pharma and big biotech activities.
Chapter 3 provides a review of the leading diagnostics deals since 2009. Deals are listed by headline value and signed by big pharm. Where the deal has an agreement contract published at the SEC a link provides online access to the contract.
Chapter 4 provides a comprehensive listing of the top 50 big pharma companies that have announced diagnsotic deals, with a brief summary followed by a comprehensive listing of diagnostics deals, as well as contract documents available in the public domain. Where available, each deal title links via Weblink to an online version of the actual contract document, providing easy access to each contract document on demand.
Chapter 5 provides a comprehensive listing of the top 50 big biotech companies that have announced diagnsotic deals, where diagnostic deals are announced with a brief summary, as well as contract documents available in the public domain. Where available, each deal title links via Weblink to an online version of the actual contract document, providing easy access to each contract document on demand.
Chapter 6 provides a comprehensive and detailed review of diagnostics partnering deals signed and announced since January 2009, where a contract document is available in the public domain. The chapter is organized by cpmpany A-Z, stage of development at signing, deal type (collaborative R&D, co-promotion, licensing etc), and specific therapy focus. Each deal title links via Weblink to an online version of the deal record and where available, the contract document, providing easy access to each contract document on demand.
Chapter 7 provides a comprehensive and detailed review of diagnostics partnering deals signed and announced since January 2009. The chapter is organized by specific diagnostics technology type in focus. Each deal title links via Weblink to an online version of the deal record and where available, the contract document, providing easy access to each contract document on demand.
The report also includes numerous tables and figures that illustrate the trends and activities in diagnostics partnering and dealmaking since 2009.
In conclusion, this report provides everything a prospective dealmaker needs to know about partnering in the research, development and commercialization of diagnostics technologies and products.
Report scope
Diagnostics Partnering Terms and Agreements is intended to provide the reader with an in-depth understanding of the diagnostic trends and structure of deals entered into by leading companies worldwide.
Diagnostics Partnering Terms and Agreements includes:
Trends in diagnostic dealmaking in the biopharma industry since 2009
Analysis of diagnostic deal structure
Case studies of real-life diagnostic deals
Access to over 3,000 diagnostic deals
The leading diagnostic deals by value since 2009
Most active diagnostic dealmakers since 2009
The leading diagnostic partnering resources
In Diagnostics Partnering Terms and Agreements , the available contracts are listed by:
Headline value
Stage of development at signing
Deal component type
Specific therapy target
Each deal title links via Weblink to online deal records of actual diagnostics partnering deals as disclosed by the deal parties. In addition, where available, records include contract documents as submitted to the Securities Exchange Commission by companies and their partners."
To view the table of contents and know more details please visit Diagnostics Partnering Terms and Agreements
No comments:
Post a Comment